MARKET

EXAI

EXAI

Exscientia Plc
NASDAQ
7.04
+1.02
+16.94%
Closed 19:13 01/31 EST
OPEN
5.95
PREV CLOSE
6.02
HIGH
7.10
LOW
5.95
VOLUME
519.15K
TURNOVER
--
52 WEEK HIGH
22.99
52 WEEK LOW
4.090
MARKET CAP
865.06M
P/E (TTM)
-7.7041
1D
5D
1M
3M
1Y
5Y
SMCI, HA and RXT are among after hour movers
Seeking Alpha · 11h ago
Schrodinger: Solving The Critical Need For AI/ML In The Biopharma Industry
Seeking Alpha · 01/22 04:46
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
VIENNA, Austria & OXFORD, England, December 06, 2022--Exscientia plc (Nasdaq: EXAI) today highlighted new data to identify patients that are more likely to respond to its A2A receptor antagonist, EXS-21546 (‘546) as well as the relationship to potential im...
Business Wire · 12/06/2022 12:00
Exscientia Receives First CTA Approval To Initiate IGNITE-AI, A Phase 1/2 Trial Of EXS-21546 In Patients With Advanced Solid Tumours
Benzinga · 11/28/2022 12:04
Exscientia Receives Approval to Initiate Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumors
Exscientia Receives Approval to Initiate Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumors
MT Newswires · 11/28/2022 08:11
Barclays Maintains Overweight Rating for Exscientia: Here's What You Need To Know
Benzinga · 11/16/2022 17:00
Barclays Maintains Overweight on Exscientia, Lowers Price Target to $12
Benzinga · 11/16/2022 11:47
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates
Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/15/2022 14:45
More
About EXAI
Exscientia PLC is a United Kingdom-based artificial intelligence-driven pharmaceutical technology company. The Company is focused on discovering, designing and developing the possible drugs. The Company has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress artificial intelligence (AI) designed small molecules into the clinical setting. The Company’s AI process is comprised of five elements, including Precision Target, Precision Design, Precision Experiment, Precision Medicine and Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the experimental underpinnings for AI-design. The Company's lead drug candidate, EXS21546, is in early stage of development.

Webull offers kinds of Exscientia PLC (ADR) stock information, including NASDAQ:EXAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAI stock methods without spending real money on the virtual paper trading platform.